Daniel M. Junius - 21 May 2021 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 May 2021, 18:15:53 UTC
Prior SEC filing
27 May 2021
Next SEC filing
03 Aug 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lily J. Lu, Attorney-in-Fact for Daniel M. Junius

Key filing fact

Daniel M. Junius filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 24 May 2021.

Key facts

  • This page summarizes Daniel M. Junius's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 24 May 2021, 18:15.

Change

  • Previous filing in this sequence was filed on 27 May 2021.
  • Current net transaction value: -$1,136,418.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value
$212,500
Shares
+2,500
Change %
+87%
Price
$85.00
Shares after
5,386
Date
21 May 2021
Ownership
Direct
IDXX transaction

Common Stock

Sale

Transaction value
$1,348,918
Shares
-2,500
Change %
-46%
Price
$539.57
Shares after
2,886
Date
21 May 2021
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Options Exercise

Transaction value
Shares
-2,500
Change %
-51%
Price
Shares after
2,402
Date
21 May 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,500
Exercise price
$85.00
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders.

Footnote F2

Not applicable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .